Oncotherapy On Track For Japan’s First Cancer Vaccine
This article was originally published in PharmAsia News
Executive Summary
Japan's Oncotherapy Science reports favorable late-phase trials on a vaccine for treating pancreatic cancer. The company said preliminary data from Phase II and III trials increase the chances for marketing approval of what would be Japan's first cancer vaccine by the end of next year. The compound being tested is OTS102, which relies on preventing formation of blood vessels in the area of a tumor. Fuso Pharmaceutical Industries has domestic marketing rights for the vaccine. (Click here for more - a subscription may be required